Study of long-acting vs daily growth hormone: peak levels, AUC, action duration, and IGF-1

Study of long-acting vs daily growth hormone : peak levels, AUC, action duration, and IGF-1 / Ashraf Soliman, Fawzia Alyafei, Nada Alaaraj, Noor Hamed, Shayma Mohamed, Ahmed Elawwa, Vincenzo De Sanctis

  • Academia Biology 2 (2024) 4, p. 1-16
  • doi.org/10.20935/AcadBiol7439

Abstract

Introduction: Long-acting growth hormone (LAGH) therapy was developed to improve adherence by reducing injection frequency compared to daily growth hormone (GH) therapy. Objectives: This review assesses the impact of LAGH therapy on serum levels of GH and insulin-like growth factor-1 (IGF-1) and evaluates the potential metabolic and safety risks compared to the natural pulsatile secretion of GH and daily GH injections in normal children.
Methods: A comprehensive literature search identified studies examining the effects of LAGH therapy on serum GH and IGF-1 levels.
Results: Studies from 2010 to 2024 were included. LAGH formulations maintain elevated IGF-1 levels for extended periods, in contrast to the episodic peaks and troughs of natural GH secretion. These formulations demonstrate efficacy in promoting growth and maintaining IGF-1 levels but are associated with sustained nonpulsatile GH exposure. Significant intra- and interindividual variability in GH uptake after injection has been observed, with higher GH concentrations correlating with increased IGF-1 levels and growth response. Concerns have been raised about adverse metabolic outcomes, including decreased insulin sensitivity. Sustained high IGF-1 levels with LAGH therapy may also increase risks for certain cancers and proliferative disorders, although evidence remains inconclusive.
Discussion: While LAGH therapy offers improved adherence, it leads to non physiological, sustained high levels of GH and IGF-1, raising concerns about long-term metabolic effects. Conclusions: LAGH therapy presents a viable alternative to daily GH injections, providing improved adherence and convenience. However, continuous monitoring of long-term metabolic and safety risks and performing long-term studies are crucial to ensuring safe and effective use in clinical practice.

Original document

Parameters

Science
Review
Date
19 December 2024
People
Alaaraj, Nada
Alyafei, Fawzia
Elawwa, Ahmed
Hamed, Noor
Mohamed, Shayma
Sanctis, Vincenzo
Soliman, Ashraf
Country
Italy
Qatar
Language
English
Other organisations
Hamad General Hospital
Doping classes
S2. Peptide Hormones, Growth Factors
Substances
Growth hormone (GH)
Insulin-like Growth Factor-1 (IGF-1)
Medical terms
Health / performance effects
Hormone replacement therapy (HRT)
Document category
Scientific article
Document type
Pdf file
Date generated
7 January 2025
Date of last modification
14 January 2025
Category
  • Legal Source
  • Education
  • Science
  • Statistics
  • History
Country & language
  • Country
  • Language
Other filters
  • ADRV
  • Legal Terms
  • Sport/IFs
  • Other organisations
  • Laboratories
  • Analytical aspects
  • Doping classes
  • Substances
  • Medical terms
  • Various
  • Version
  • Document category
  • Document type
Publication period
Origin